{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:34:29Z","timestamp":1789043669316,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We examined the impact of total body irradiation (TBI) dose and fractionation on risk of subsequent malignant neoplasms (SMNs) in the era of reduced-intensity and nonmyeloablative conditioning regimens for hematopoietic cell transplantation (HCT). Among 4905 1-year survivors of allogeneic HCT for hematologic malignancies (N = 4500) or nonmalignant disorders (N = 405) who received transplants between 1969 and 2014, we identified 581 SMNs (excluding squamous and basal cell of skin) in 499 individuals. With a median length of follow-up of 12.5 years, the cumulative incidence of SMNs by 30 years after HCT was 22.0%. Compared with age-, sex-, and calendar year\u2013matched Surveillance, Epidemiology, and End Results (SEER) population rates, the standardized incidence ratio (SIR) of SMNs was increased 2.8-fold. The highest SIRs were for SMNs of bones (SIR, 28.8), oral cavity (SIR, 13.8), skin (SIR, 7.3), central nervous system (SIR, 6.0), and endocrine organs (SIR, 4.9). The highest excess absolute risks (EARs) were seen with breast cancer (EAR, 2.2) and cancers of the oral cavity (EAR, 1.5) and skin (EAR, 1.5) per 1000 person-years. The highest incidence of SMNs was in survivors exposed to unfractionated (600-1000 cGy) or high-dose fractionated (1440-1750 cGy) TBI. For patients receiving low-dose TBI, the incidence was comparable to myeloablative chemotherapy alone, although still twofold higher than in the general population. These data demonstrate a strong effect of TBI dose, dose fractionation, and risk of SMNs after HCT. The cumulative incidence of SMNs increases with follow-up time; thus, HCT survivors require lifetime monitoring for early detection and effective therapy of SMNs.<\/jats:p>","DOI":"10.1182\/blood.2018874115","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:54:08Z","timestamp":1555455248000},"page":"2790-2799","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":126,"title":["Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation"],"prefix":"10.1182","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-1648","authenticated-orcid":false,"given":"K. Scott","family":"Baker","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy M.","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-0943","authenticated-orcid":false,"given":"Ralph P.","family":"Ermoian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schoch","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-4099","authenticated-orcid":false,"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-9739","authenticated-orcid":false,"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2020021108422689600_B1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"2020021108422689600_B2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/bmt.2012.258","article-title":"Surviving the cure: long term followup of hematopoietic cell transplant recipients","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2020021108422689600_B3","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2020021108422689600_B4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021108422689600_B5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2000.18.2.348","article-title":"New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia","volume":"18","author":"Soci\u00e9","year":"2000","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020021108422689600_B6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"2020021108422689600_B7","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021108422689600_B8","first-page":"33","article-title":"Secondary malignancies after marrow transplantation for leukemia or aplastic anemia","volume":"4","author":"Witherspoon","year":"1994","journal-title":"Transplant Sci"},{"issue":"7","key":"2020021108422689600_B9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2005.02.7052","article-title":"Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation","volume":"24","author":"Leisenring","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021108422689600_B10","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.1998.16.7.2570","article-title":"Second cancers after pediatric Hodgkin\u2019s disease","volume":"16","author":"Bhatia","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021108422689600_B11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nrc722","article-title":"Second cancers in survivors of childhood cancer","volume":"2","author":"Bhatia","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2020021108422689600_B12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM198909213211203","article-title":"Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia","volume":"321","author":"Witherspoon","year":"1989","journal-title":"N Engl J Med"},{"issue":"12","key":"2020021108422689600_B13","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108422689600_B14","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood.V88.9.3634.bloodjournal8893634","article-title":"FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors","volume":"88","author":"Nash","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2020021108422689600_B15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.V73.6.1729.1729","article-title":"Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial","volume":"73","author":"Storb","year":"1989","journal-title":"Blood"},{"issue":"5","key":"2020021108422689600_B16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbmt.2013.02.006","article-title":"Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects","volume":"19","author":"Storb","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021108422689600_B17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"2020021108422689600_B18","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1182\/blood-2006-05-021139","article-title":"A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease","volume":"109","author":"Hockenbery","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2020021108422689600_B19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"key":"2020021108422689600_B20","first-page":"113","article-title":"Second cancer following cancer of the female genital system in Connecticut, 1935-82","volume":"68","author":"Curtis","year":"1985","journal-title":"Natl Cancer Inst Monogr"},{"key":"2020021108422689600_B21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000060439","article-title":"Secondary malignancies after allogeneic or autologous marrow transplantation","volume-title":"Secondary Neoplasias following Chemotherapy, Radiotherapy, and Immunosuppression","author":"Witherspoon","year":"2000"},{"key":"2020021108422689600_B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/B978-0-12-035405-4.50012-8","article-title":"The four R\u2019s of radiotherapy","volume":"5","author":"Withers","year":"1975","journal-title":"Adv Radiat Biol"},{"issue":"1","key":"2020021108422689600_B23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12920-015-0097-x","article-title":"Radiation dose-rate effects on gene expression for human biodosimetry","volume":"8","author":"Ghandhi","year":"2015","journal-title":"BMC Med Genomics"},{"issue":"6","key":"2020021108422689600_B24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1667\/RR2483.1","article-title":"Global gene expression responses to low- or high-dose radiation in a human three-dimensional tissue model","volume":"175","author":"Mezentsev","year":"2011","journal-title":"Radiat Res"},{"issue":"18","key":"2020021108422689600_B25","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1182\/blood-2011-07-365247","article-title":"Inhibition of IL-32 activation by \u03b1-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model","volume":"118","author":"Marcondes","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2020021108422689600_B26","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/carcin\/bgn193","article-title":"Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk","volume":"29","author":"Smith","year":"2008","journal-title":"Carcinogenesis"},{"issue":"5","key":"2020021108422689600_B27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2020021108422689600_B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2020021108422689600_B29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2002-01-0011","article-title":"Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial","volume":"100","author":"Flowers","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2020021108422689600_B30","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1182\/blood-2004-09-3411","article-title":"Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study","volume":"105","author":"Curtis","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2020021108422689600_B31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2011-01-331835","article-title":"Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020021108422689600_B32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2014.01.009","article-title":"Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"20","author":"Gyurkocza","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/26\/2790\/1557583\/blood874115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/26\/2790\/1557583\/blood874115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:24:04Z","timestamp":1581413044000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/26\/2790\/272767\/Total-body-irradiation-dose-and-risk-of-subsequent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":32,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018874115","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]}}}